Prestige Consumer Healthcare (NYSE:PBH) Rating Lowered to Hold at StockNews.com

Prestige Consumer Healthcare (NYSE:PBH) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Friday.

PBH has been the topic of a number of other reports. DA Davidson boosted their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Canaccord Genuity Group boosted their target price on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. Royal Bank of Canada raised Prestige Consumer Healthcare to a “hold” rating in a report on Thursday. Finally, Oppenheimer increased their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research report on Thursday, February 13th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of “Hold” and a consensus price target of $93.33.

Prestige Consumer Healthcare Stock Performance

Shares of PBH stock opened at $87.65 on Friday. Prestige Consumer Healthcare has a 52-week low of $62.35 and a 52-week high of $90.04. The stock’s 50-day moving average price is $83.18 and its 200 day moving average price is $81.39. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $4.34 billion, a PE ratio of 20.53, a price-to-earnings-growth ratio of 2.69 and a beta of 0.44.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Thursday, May 8th. The company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.30 by $0.02. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. The business had revenue of $296.52 million during the quarter, compared to analysts’ expectations of $289.36 million. During the same quarter in the prior year, the business earned $1.02 earnings per share. The company’s quarterly revenue was up 7.0% compared to the same quarter last year. As a group, equities research analysts forecast that Prestige Consumer Healthcare will post 4.5 EPS for the current year.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $90.00, for a total value of $151,020.00. Following the sale, the senior vice president now owns 17,157 shares of the company’s stock, valued at $1,544,130. This represents a 8.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PBH. Barclays PLC raised its holdings in shares of Prestige Consumer Healthcare by 346.3% in the third quarter. Barclays PLC now owns 92,444 shares of the company’s stock worth $6,665,000 after acquiring an additional 71,730 shares during the last quarter. Franklin Resources Inc. raised its stake in Prestige Consumer Healthcare by 4.3% in the 3rd quarter. Franklin Resources Inc. now owns 21,585 shares of the company’s stock valued at $1,513,000 after purchasing an additional 894 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Prestige Consumer Healthcare by 3.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company’s stock valued at $19,630,000 after purchasing an additional 8,533 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Prestige Consumer Healthcare by 18.9% during the 4th quarter. GAMMA Investing LLC now owns 1,383 shares of the company’s stock worth $108,000 after purchasing an additional 220 shares during the last quarter. Finally, Nordea Investment Management AB grew its holdings in shares of Prestige Consumer Healthcare by 3.4% during the fourth quarter. Nordea Investment Management AB now owns 90,693 shares of the company’s stock worth $7,066,000 after buying an additional 2,985 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.